Embecta Investors Face Class Action After Dividend Cut and EPS Collapse

The litigation centers on whether Embecta misled shareholders by repeatedly characterizing its pen needle business as stable and durable. During the class period, the company reiterated an adjusted EPS guidance of $2.80 to $3.00, while emphasizing its commitment to existing dividend levels. However, the reality surfaced on May 5, 2026, when the firm reported a 61% decline in adjusted EPS to just $0.27.

Following the earnings miss, management slashed the annual EPS guidance to a range of $1.55 to $1.75 and cut the dividend by 93% to a mere $0.01 per share. Hagens Berman, the firm leading the investigation, claims Embecta management knew or recklessly disregarded significant market weaknesses that were poised to undermine their financial projections. Investors seeking to serve as lead plaintiffs in the case have until August 17, 2026, to submit their claims.